MX2018002738A - Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. - Google Patents

Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.

Info

Publication number
MX2018002738A
MX2018002738A MX2018002738A MX2018002738A MX2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A MX 2018002738 A MX2018002738 A MX 2018002738A
Authority
MX
Mexico
Prior art keywords
present disclosure
derivatives
compounds
medicaments
tricyclic fused
Prior art date
Application number
MX2018002738A
Other languages
English (en)
Inventor
Sridharan Rajagopal
Vadivelu Saravanan
Chinnapattu Murugan
Kumar Gondrala Pavan
Sivanandhan Dhanalakshmi
Mulakala Chandrika
Kiran Parikh Payal
M Ramaiah Manjunatha
Original Assignee
Jubilant Biosys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57346000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018002738(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jubilant Biosys Ltd filed Critical Jubilant Biosys Ltd
Publication of MX2018002738A publication Critical patent/MX2018002738A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

La presente descripción describe compuestos heterocíclicos de fórmula I: (ver Fórmula) o sus estereoisómeros, sales farmacéuticamente aceptables, complejos, hidratos, solvatos, tautómeros, polimorfos, mezclas racémicas, formas ópticamente activas y derivados farmacéuticamente activos del mismo y composiciones farmacéuticas que los contienen como el ingrediente activo; la presente descripción describe también la síntesis y caracterización de los compuestos mencionados anteriormente que exhiben alta actividad anti-cáncer; los compuestos de la presente descripción son útiles como medicamentos y su uso en la fabricación de medicamentos para el tratamiento, prevención o supresión de enfermedades y condiciones mediadas por uno o más bromodominios de la familia BET.
MX2018002738A 2015-09-09 2016-09-08 Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4. MX2018002738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4781CH2015 2015-09-09
PCT/IN2016/050300 WO2017042834A1 (en) 2015-09-09 2016-09-08 Tricyclic fused pyridin-2-one derivatives and their use as brd4 inhibitors

Publications (1)

Publication Number Publication Date
MX2018002738A true MX2018002738A (es) 2018-04-13

Family

ID=57346000

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002738A MX2018002738A (es) 2015-09-09 2016-09-08 Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.

Country Status (22)

Country Link
US (2) US10689395B2 (es)
EP (1) EP3347356B1 (es)
JP (1) JP6838052B2 (es)
KR (1) KR20180049056A (es)
CN (1) CN108137588B (es)
AU (1) AU2016319638B2 (es)
CA (1) CA2997531A1 (es)
CY (1) CY1124245T1 (es)
DK (1) DK3347356T3 (es)
ES (1) ES2866073T3 (es)
HK (1) HK1251562A1 (es)
HR (1) HRP20210581T1 (es)
HU (1) HUE053912T2 (es)
IL (1) IL257473B (es)
LT (1) LT3347356T (es)
MX (1) MX2018002738A (es)
PL (1) PL3347356T3 (es)
PT (1) PT3347356T (es)
RS (1) RS61803B1 (es)
RU (1) RU2734959C2 (es)
SI (1) SI3347356T1 (es)
WO (1) WO2017042834A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017504653A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアミノピリミジンベンゼンスルホン誘導体およびその使用
BR112018004617A2 (pt) 2015-09-11 2018-09-25 Dana Farber Cancer Inst Inc acetamida tienotriazoldiazepinas e usos das mesmas
JP2018526421A (ja) 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド シアノチエノトリアゾロジアゼピンおよびこれらの使用
KR20180081809A (ko) 2015-11-25 2018-07-17 다나-파버 캔서 인스티튜트 인크. 2가 브로모도메인 억제제 및 그의 용도
CN108069976A (zh) * 2016-11-10 2018-05-25 山东罗欣药业集团股份有限公司 一种含氮大环类化合物、其制备方法、药物组合物及应用
CN112119065B (zh) * 2018-07-13 2024-01-23 四川科伦博泰生物医药股份有限公司 苯并二氮杂环类化合物、其制备方法及用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904403A (en) 2007-04-25 2009-02-01 Daiichi Sankyo Co Ltd Tricyclic aryl compounds
US8263633B2 (en) 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
JP6419735B2 (ja) * 2013-03-12 2018-11-07 アッヴィ・インコーポレイテッド 四環系ブロモドメイン阻害剤
JP6764877B2 (ja) * 2015-03-30 2020-10-07 ジュビラント バイオシス リミテッドＪｕｂｉｌａｎｔ Ｂｉｏｓｙｓ Ｌｉｍｉｔｅｄ がん治療に有用な１−（シクロ）アルキルピリジン−２−オンの三環式縮合誘導体

Also Published As

Publication number Publication date
AU2016319638B2 (en) 2021-02-11
JP6838052B2 (ja) 2021-03-03
HK1251562A1 (zh) 2019-02-01
CA2997531A1 (en) 2017-03-16
RU2734959C2 (ru) 2020-10-26
US20180237453A1 (en) 2018-08-23
CN108137588B (zh) 2021-06-18
BR112018004338A2 (pt) 2018-10-09
EP3347356B1 (en) 2021-03-24
LT3347356T (lt) 2021-06-10
CY1124245T1 (el) 2022-07-22
PL3347356T3 (pl) 2021-08-16
CN108137588A (zh) 2018-06-08
DK3347356T3 (da) 2021-04-26
SI3347356T1 (sl) 2021-08-31
JP2018529673A (ja) 2018-10-11
WO2017042834A1 (en) 2017-03-16
RS61803B1 (sr) 2021-06-30
EP3347356A1 (en) 2018-07-18
HRP20210581T1 (hr) 2021-05-28
PT3347356T (pt) 2021-06-28
IL257473A (en) 2018-04-30
US10689395B2 (en) 2020-06-23
US20200339595A1 (en) 2020-10-29
ES2866073T3 (es) 2021-10-19
KR20180049056A (ko) 2018-05-10
AU2016319638A1 (en) 2018-03-15
HUE053912T2 (hu) 2021-07-28
RU2018112015A (ru) 2019-10-11
RU2018112015A3 (es) 2019-10-11
IL257473B (en) 2021-12-01
US11267820B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
MX2018002738A (es) Derivados de piridin-2-ona fusionados triciclicos, y su uso como inhibidores de brd4.
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
PH12016501440A1 (en) Novel heterocyclic compounds
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MX2022010520A (es) Macrociclos peptidicos contra acinetobacter baumannii.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
MX2019003143A (es) Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico.
MY175854A (en) Novel quinolone derivatives
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
IN2014CN00408A (es)
MD20160132A2 (ro) Săruri de adiţie ale (S)-2-(1-(6-amino-5-cianopirimidin-4-ilamino)etil)-4-oxo-3-fenil-3,4-dihidropirolo[1,2-f][1,2,4]triazin-5-carbonitrilului
MY180666A (en) Substituted pyrazolo [3,4-b] pyridines as medicaments
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
PH12017501699A1 (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
PH12016501903B1 (en) Novel fused imidazobenzothiazole compounds
MX2017012387A (es) Derivados fusionados triciclicos de 1-(ciclo)alquil piridin-2-ona utiles para el tratamiento de cancer.
WO2014014794A3 (en) Mineralocorticoid receptor antagonists
MX2017008495A (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
MX2018014165A (es) Compuestos heterociclicos utiles como agentes antibacterianos y metodo de produccion.
IN2015MN00045A (es)
PH12017500323B1 (en) P38 map kinase inhibiting indanyl urea compounds